{"id":10409,"date":"2026-07-25T20:38:48","date_gmt":"2026-07-25T17:38:48","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10409"},"modified":"2026-07-25T20:38:48","modified_gmt":"2026-07-25T17:38:48","slug":"esc-congress-2026-to-feature-59-late-breaking-clinical-trials","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/esc-congress-2026-to-feature-59-late-breaking-clinical-trials\/","title":{"rendered":"ESC Congress 2026 to Feature 59 Late-Breaking Clinical Trials"},"content":{"rendered":"<p><span>ESC Congress 2026 to Feature 59 Late-Breaking Clinical Trials<\/span><\/p>\n<p><span>Source: ESC Congress 2026. July 2026<\/span><\/p>\n<p><span>* 59 late-breaking trials will be presented in 12 Hot Line sessions at ESC Congress 2026 (Munich, Aug. 28\u201331).<\/span><br \/>\n<span>* The program includes major studies on ACS, heart failure, atrial fibrillation, TAVI, hypertrophic cardiomyopathy, cardiac amyloidosis, imaging, digital health, and prevention.<\/span><br \/>\n<span>* Key highlighted trials include LIBREXIA ACS, PRESC1SE-MI, CARDIO-TTRansform, ACACIA-HCM, and STAREE.<\/span><br \/>\n<span>* ESC expects several of these studies to shape future clinical guidelines and cardiovascular practice.<\/span><\/p>\n<p><a href=\"https:\/\/www.escardio.org\/news\/press\/press-releases\/hot-lines-revealed--the-trials-that-will-make-the-headlines-at-esc-congress-2026\/\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.escardio.org\/news\/press\/press-releases\/hot-lines-revealed--the-trials-that-will-make-the-headlines-at-esc-congress-2026\/&amp;source=gmail&amp;ust=1785087486393000&amp;usg=AOvVaw193b78apqUMGI7Fi2t7jDT\" rel=\"noopener\">https:\/\/www.escardio.org\/news\/<wbr \/>press\/press-releases\/hot-<wbr \/>lines-revealed&#8211;the-trials-<wbr \/>that-will-make-the-headlines-<wbr \/>at-esc-congress-2026\/<\/a><span>?<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ESC Congress 2026 to Feature 59 Late-Breaking Clinical Trials Source: ESC Congress 2026. July 2026 * 59 late-breaking trials will be presented in 12 Hot Line sessions at ESC Congress 2026 (Munich, Aug. 28\u201331). * The program includes major studies on ACS, heart failure, atrial fibrillation, TAVI, hypertrophic cardiomyopathy, cardiac amyloidosis, imaging, digital health, and [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10409","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10409"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10409\/revisions"}],"predecessor-version":[{"id":10410,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10409\/revisions\/10410"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}